Bulletin
Investor Alert

Market Pulse Archives

Dec. 6, 2019, 10:58 a.m. EST

Cassava stock is up on Alzheimer's data

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Cassava Sciences Inc. (SAVA)
  • X
    Biogen Inc. (BIIB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Cassava Sciences Inc. /zigman2/quotes/204212356/composite SAVA -7.18% jumped 24% on positive data from a mid-stage trial for its experimental Alzheimer's disease drug, PTI-125. The data, which found that the therapy reduced cerebrospinal fluid and plasma biomarkers for Alzheimer's, was released Dec. 5 at the Clinical Trials on Alzheimer's Disease meeting in San Diego. Biogen /zigman2/quotes/201531540/composite BIIB -2.14% also released somewhat controversial data about its late-stage Alzheimer's candidate at the conference on Thursday. Cassava stock is up 163% year-to-date. The S&P 500 /zigman2/quotes/210599714/realtime SPX -0.90% is up 25%.

/zigman2/quotes/204212356/composite
US : U.S.: Nasdaq
$ 7.18
-0.56 -7.18%
Volume: 1.49M
Jan. 24, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$123.55 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/201531540/composite
US : U.S.: Nasdaq
$ 278.14
-6.07 -2.14%
Volume: 1.26M
Jan. 24, 2020 4:00p
P/E Ratio
9.89
Dividend Yield
N/A
Market Cap
$50.19 billion
Rev. per Employee
$1.55M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,295.47
-30.07 -0.90%
Volume: 2.11B
Jan. 24, 2020 5:00p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.